Researchers from Tikkunlev Therapeutics Inc. and the University of Utah have presented preclinical data on TLT-101, a gene therapy consisting of an adeno-associated virus serotype 9 (AAV9) vector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback